Evelyne Meekers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evelyne Meekers has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Wilfried Mullens
Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk
5 shared publications - Matthias Dupont
Cardiology Department, Ziekenhuis Oost-Limburg , Genk
4 shared publications - Pieter Martens
Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Genk
4 shared publications - Sebastiaan Dhont
Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium; Doctoral School of Medicine and Life Sciences, Limburg Clinical Research Center, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
4 shared publications Frank Ruschitzka
Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Switzerland (F.R.).
3 shared publications- Frederik Hendrik Verbrugge
Centre for Cardiovascular Diseases, University Hospital Brussels , Jette
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Impact of obesity on clinical outcomes and the treatment effect of catheter ablation in atrial fibrillation: insights from CABANA
Aims: Obesity and atrial fibrillation (AF) are global epidemics, often co-existing and compounding cardiovascular risk. While catheter ablation has emerged as an effective strategy for rhythm control in symptomatic AF, it remains unclear whether obesity modifies its benefit. This post hoc analysis of the CABANA trial investigates the influence of baseline obesity on clinical outcomes after catheter ablation vs. drug therapy in AF patients. Methods and results: A total of 2170 CABANA participants with available body mass index (BMI) were included. Obesity was defined by BMI ≥ 30 kg/m2, and Class II obesity by BMI ≥ 35 kg/m2. Adverse outcomes, AF recurrence, and functional status were analysed using Cox, mixed-effects, and generalized estimating equation models, assessing treatment-by-obesity interactions. Obese patients exhibited higher comorbidity burden, worse baseline functional status, and more persistent AF compared to non-obese counterparts. Higher BMI was associated with increased cardiovascular hospitalization and a higher New York Heart Association functional class. Catheter ablation significantly reduced the risk of AF recurrence and improved symptom burden and functional capacity, irrespective of obesity status. No significant interaction was found between BMI and treatment effect on the primary composite endpoint of cardiovascular hospitalization or all-cause mortality. However, patients with Class II obesity or higher had worse absolute outcomes despite similar relative benefits from ablation. Conclusion: While obesity is associated with worse baseline status and outcomes, it was not shown to significantly alter the relative effectiveness of AF ablation compared to drug therapy. These findings support a multifaceted approach integrating rhythm control with upstream interventions targeting obesity-related atrial remodelling and comorbidity management.
- 1 October 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Open AccessImpact of obesity on clinical outcomes and the treatment effect of catheter ablation in atrial fibrillation: insights from CABANA
Aims: Obesity and atrial fibrillation (AF) are global epidemics, often co-existing and compounding cardiovascular risk. While catheter ablation has emerged as an effective strategy for rhythm control in symptomatic AF, it remains unclear whether obesity modifies its benefit. This post hoc analysis of the CABANA trial investigates the influence of baseline obesity on clinical outcomes after catheter ablation vs. drug therapy in AF patients. Methods and results: A total of 2170 CABANA participants with available body mass index (BMI) were included. Obesity was defined by BMI ≥ 30 kg/m2, and Class II obesity by BMI ≥ 35 kg/m2. Adverse outcomes, AF recurrence, and functional status were analysed using Cox, mixed-effects, and generalized estimating equation models, assessing treatment-by-obesity interactions. Obese patients exhibited higher comorbidity burden, worse baseline functional status, and more persistent AF compared to non-obese counterparts. Higher BMI was associated with increased cardiovascular hospitalization and a higher New York Heart Association functional class. Catheter ablation significantly reduced the risk of AF recurrence and improved symptom burden and functional capacity, irrespective of obesity status. No significant interaction was found between BMI and treatment effect on the primary composite endpoint of cardiovascular hospitalization or all-cause mortality. However, patients with Class II obesity or higher had worse absolute outcomes despite similar relative benefits from ablation. Conclusion: While obesity is associated with worse baseline status and outcomes, it was not shown to significantly alter the relative effectiveness of AF ablation compared to drug therapy. These findings support a multifaceted approach integrating rhythm control with upstream interventions targeting obesity-related atrial remodelling and comorbidity management.
- 29 July 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (8) , 901-908
Acetazolamide, residual congestion and clinical outcomes in acute heart failure – a prespecified analysis of the ADVOR trial
Heart failure is a global problem with increasing incidence and prevalence worldwide. Signs and symptoms of congestion are the main reason for patients with heart failure to seek medical attention....
- 29 July 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (8) , 901-908
Acetazolamide, residual congestion and clinical outcomes in acute heart failure – a prespecified analysis of the ADVOR trial
Heart failure is a global problem with increasing incidence and prevalence worldwide. Signs and symptoms of congestion are the main reason for patients with heart failure to seek medical attention....
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 1973-1983
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial
BACKGROUND: Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsartan reduces functional mitral regurgitation (MR) in HF with reduced EF (HFrEF), its impact on exercise hemodynamics and the dynamic burden of AFMR in HFpEF remains to be elucidated. METHODS: This multicenter, randomized, open-label trial with blinded primary endpoint assessment assigned 84 patients with symptomatic HFpEF and at least moderate AFMR within the previous year to sacubitril/valsartan (n=41) or standard-of-care (SOC; n=43). The primary outcome was the 6-month change in the exercise mean pulmonary arterial pressure to cardiac output (mPAP/CO) slope, assessed using cardiopulmonary exercise testing with simultaneous echocardiography (CPETecho). Secondary outcomes included changes in peak oxygen consumption (peak VO 2 ), Kansas City Cardiomyopathy Questionnaire (KCCQ), N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, left atrial (LA) volume and function, and AFMR severity in rest and during stress. RESULTS: At 6 months, sacubitril/valsartan significantly improved the mPAP/CO slope compared with SOC (adjusted between-group difference in change, –0.93 mm Hg/L/min; 95% CI, –1.80 to –0.07; P =0.035). This hemodynamic benefit was accompanied by improvements in peak VO 2 (mean change, +0.9 versus –0.6mL/kg/min; P =0.002) and KCCQ (median increase, 10 versus 2 points; P =0.002). Significant reductions in NT-proBNP and LA volume were observed ( P P =0.020). Target dose was achieved in 60% of patients, with symptomatic hypotension as the primary titration-limiting factor. CONCLUSIONS: In HFpEF and AFMR, sacubitril/valsartan was associated with improvements in exercise hemodynamics and peak VO 2 , along with attenuation of the exercise-induced increase in AFMR. These findings suggest a phenotype-specific benefit, warranting confirmation in larger, placebo-controlled, clinical outcome trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05991284. EudraCT: 2023-506634-70-00
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (25) , 1973-1983
Angiotensin Receptor Neprilysin Inhibitor in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Regurgitation: The PRAISE-MR Randomized Trial
BACKGROUND: Atrial functional mitral regurgitation (AFMR) characterizes a high-risk phenotype in heart failure with preserved ejection fraction (HFpEF). Although sacubitril/valsartan reduces functional mitral regurgitation (MR) in HF with reduced EF (HFrEF), its impact on exercise hemodynamics and the dynamic burden of AFMR in HFpEF remains to be elucidated. METHODS: This multicenter, randomized, open-label trial with blinded primary endpoint assessment assigned 84 patients with symptomatic HFpEF and at least moderate AFMR within the previous year to sacubitril/valsartan (n=41) or standard-of-care (SOC; n=43). The primary outcome was the 6-month change in the exercise mean pulmonary arterial pressure to cardiac output (mPAP/CO) slope, assessed using cardiopulmonary exercise testing with simultaneous echocardiography (CPETecho). Secondary outcomes included changes in peak oxygen consumption (peak VO 2 ), Kansas City Cardiomyopathy Questionnaire (KCCQ), N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, left atrial (LA) volume and function, and AFMR severity in rest and during stress. RESULTS: At 6 months, sacubitril/valsartan significantly improved the mPAP/CO slope compared with SOC (adjusted between-group difference in change, –0.93 mm Hg/L/min; 95% CI, –1.80 to –0.07; P =0.035). This hemodynamic benefit was accompanied by improvements in peak VO 2 (mean change, +0.9 versus –0.6mL/kg/min; P =0.002) and KCCQ (median increase, 10 versus 2 points; P =0.002). Significant reductions in NT-proBNP and LA volume were observed ( P P =0.020). Target dose was achieved in 60% of patients, with symptomatic hypotension as the primary titration-limiting factor. CONCLUSIONS: In HFpEF and AFMR, sacubitril/valsartan was associated with improvements in exercise hemodynamics and peak VO 2 , along with attenuation of the exercise-induced increase in AFMR. These findings suggest a phenotype-specific benefit, warranting confirmation in larger, placebo-controlled, clinical outcome trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05991284. EudraCT: 2023-506634-70-00
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (2) , e013584
Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial
BACKGROUND: Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose. METHODS: In this single-center, prospective, open-label, core-laboratory blinded trial, a total of 30 patients with an aorto-ostial right coronary artery lesion were randomly assigned to either percutaneous coronary intervention with a preprocedural 3DCT or angiography-guided percutaneous coronary intervention. The optimal working view angle was determined by 3DCT in the intervention group and by the operators’ discretion in the control group. The primary end point was the percentage of patients without geographic mismatch, as determined by intravascular ultrasound. RESULTS: 3DCT-determined C-arm angles were heterogenous but, in general, more extreme left anterior oblique projections were used ( P P =0.06). The mean amount of procedural contrast ( P P =0.03), and median procedure time ( P =0.03) were significantly lower in the intervention group. The 3DCT scan was able to predict the calcium arc ( P P =0.003). CONCLUSIONS: Preprocedural 3DCT planning for percutaneous coronary intervention of aorto-ostial right coronary artery lesions allows for optimal stent positioning while reducing procedure time, contrast, and radiation dose. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05172323.
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (2) , e013584
Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial
BACKGROUND: Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose. METHODS: In this single-center, prospective, open-label, core-laboratory blinded trial, a total of 30 patients with an aorto-ostial right coronary artery lesion were randomly assigned to either percutaneous coronary intervention with a preprocedural 3DCT or angiography-guided percutaneous coronary intervention. The optimal working view angle was determined by 3DCT in the intervention group and by the operators’ discretion in the control group. The primary end point was the percentage of patients without geographic mismatch, as determined by intravascular ultrasound. RESULTS: 3DCT-determined C-arm angles were heterogenous but, in general, more extreme left anterior oblique projections were used ( P P =0.06). The mean amount of procedural contrast ( P P =0.03), and median procedure time ( P =0.03) were significantly lower in the intervention group. The 3DCT scan was able to predict the calcium arc ( P P =0.003). CONCLUSIONS: Preprocedural 3DCT planning for percutaneous coronary intervention of aorto-ostial right coronary artery lesions allows for optimal stent positioning while reducing procedure time, contrast, and radiation dose. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05172323.
- 1 October 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (10) , e011749
Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial
BACKGROUND: Chloride plays a crucial role in renal salt sensing. This study investigates whether serum chloride is associated with clinical outcomes and decongestive response to acetazolamide in patients with acute decompensated heart failure. METHODS: This post hoc analysis includes all 519 patients from the ADVOR trial (Acetazolamide in Decompensated Heart Failure With Volume Overload), randomized to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The impact of baseline serum chloride on the main trial end points and the treatment effect of acetazolamide was assessed, as was the evolution of serum chloride under decongestive treatment. RESULTS: Hypochloremia (106 mmol/L) were present in 80 (15%) and 53 (10%), respectively, at baseline. Hypochloremia was associated with significantly slower decongestion, a longer length of hospital stay, and increased risk of all-cause mortality and heart failure readmissions. Acetazolamide increased the odds of successful decongestion and reduced length of stay irrespectively of baseline serum chloride levels. No statistically significant interaction between serum chloride levels and the effect of acetazolamide on death or heart failure readmissions was observed. The placebo group exhibited a progressive decline in serum chloride, which was effectively prevented by acetazolamide ( P <0.001). CONCLUSIONS: Hypochloremia is associated with diuretic resistance and worse clinical outcomes. Add-on acetazolamide therapy improves decongestion across the entire range of serum chloride and prevents the drop in chloride levels caused by loop diuretic monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03505788
- 1 October 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (10) , e011749
Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial
BACKGROUND: Chloride plays a crucial role in renal salt sensing. This study investigates whether serum chloride is associated with clinical outcomes and decongestive response to acetazolamide in patients with acute decompensated heart failure. METHODS: This post hoc analysis includes all 519 patients from the ADVOR trial (Acetazolamide in Decompensated Heart Failure With Volume Overload), randomized to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The impact of baseline serum chloride on the main trial end points and the treatment effect of acetazolamide was assessed, as was the evolution of serum chloride under decongestive treatment. RESULTS: Hypochloremia (106 mmol/L) were present in 80 (15%) and 53 (10%), respectively, at baseline. Hypochloremia was associated with significantly slower decongestion, a longer length of hospital stay, and increased risk of all-cause mortality and heart failure readmissions. Acetazolamide increased the odds of successful decongestion and reduced length of stay irrespectively of baseline serum chloride levels. No statistically significant interaction between serum chloride levels and the effect of acetazolamide on death or heart failure readmissions was observed. The placebo group exhibited a progressive decline in serum chloride, which was effectively prevented by acetazolamide ( P <0.001). CONCLUSIONS: Hypochloremia is associated with diuretic resistance and worse clinical outcomes. Add-on acetazolamide therapy improves decongestion across the entire range of serum chloride and prevents the drop in chloride levels caused by loop diuretic monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03505788
- Open Access
- 20 August 2024
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 20 (4) , 42-53
Role of Imaging and Biomarkers in Identifying, Monitoring, and Promoting Myocardial Recovery
Reverse remodeling, the overarching concept behind myocardial recovery, describes the process in which the maladaptive cardiac structural and functional alterations are reversed by removing the underlying etiology or by therapy. This review addresses different imaging modalities and biomarkers as possible predictors for reverse remodeling in patients with chronic heart failure. Although echocardiography remains the imaging modality of choice in daily practice, the presence and amount of fibrosis on cardiac magnetic resonance is a better predictor and inversely correlated with the likelihood for reverse remodeling. A decrease in NT-proBNP levels and serum soluble ST3 during follow-up is associated with better clinical and structural outcomes. The role of troponins and galectine-3 is less clear. There is a promising role for microRNAs in the future, although more research is necessary. Accurate predictors of reverse remodeling could help identify patients with an increased likelihood for reverse remodeling and, in turn, improve patient-tailored medicine.
- 20 August 2024
- Published by Houston Methodist DeBakey Heart & Vascular Center in Methodist DeBakey Cardiovascular Journal
- Vol. 20 (4) , 42-53
Open AccessRole of Imaging and Biomarkers in Identifying, Monitoring, and Promoting Myocardial Recovery
Reverse remodeling, the overarching concept behind myocardial recovery, describes the process in which the maladaptive cardiac structural and functional alterations are reversed by removing the underlying etiology or by therapy. This review addresses different imaging modalities and biomarkers as possible predictors for reverse remodeling in patients with chronic heart failure. Although echocardiography remains the imaging modality of choice in daily practice, the presence and amount of fibrosis on cardiac magnetic resonance is a better predictor and inversely correlated with the likelihood for reverse remodeling. A decrease in NT-proBNP levels and serum soluble ST3 during follow-up is associated with better clinical and structural outcomes. The role of troponins and galectine-3 is less clear. There is a promising role for microRNAs in the future, although more research is necessary. Accurate predictors of reverse remodeling could help identify patients with an increased likelihood for reverse remodeling and, in turn, improve patient-tailored medicine.
- Open Access
- 30 March 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (4)
Real-world validation of smartphone-based photoplethysmography for rate and rhythm monitoring in atrial fibrillation
Photoplethysmography- (PPG) based smartphone applications facilitate heart rate and rhythm monitoring in patients with paroxysmal and persistent atrial fibrillation (AF). Despite an endorsement from the European Heart Rhythm Association, validation studies in this setting are lacking. Therefore, we evaluated the accuracy of PPG-derived heart rate and rhythm classification in subjects with an established diagnosis of AF in unsupervised real-world conditions. Fifty consecutive patients were enrolled, 4 weeks before undergoing AF ablation. Patients used a handheld single-lead electrocardiography (ECG) device and a fingertip PPG smartphone application to record 3907 heart rhythm measurements twice daily during 8 weeks. The ECG was performed immediately before and after each PPG recording and was given a diagnosis by the majority of three blinded cardiologists. A consistent ECG diagnosis was exhibited along with PPG data of sufficient quality in 3407 measurements. A single measurement exhibited good quality more often with ECG (93.2%) compared to PPG (89.5%; P < 0.001). However, PPG signal quality improved to 96.6% with repeated measurements. Photoplethysmography-based detection of AF demonstrated excellent sensitivity [98.3%; confidence interval (CI): 96.7–99.9%], specificity (99.9%; CI: 99.8–100.0%), positive predictive value (99.6%; CI: 99.1–100.0%), and negative predictive value (99.6%; CI: 99.0–100.0%). Photoplethysmography underestimated the heart rate in AF with 6.6 b.p.m. (95% CI: 5.8 b.p.m. to 7.4 b.p.m.). Bland–Altman analysis revealed increased underestimation in high heart rates. The root mean square error was 11.8 b.p.m. Smartphone applications using PPG can be used to monitor patients with AF in unsupervised real-world conditions. The accuracy of AF detection algorithms in this setting is excellent, but PPG-derived heart rate may tend to underestimate higher heart rates.
- 30 March 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (4)
Open AccessReal-world validation of smartphone-based photoplethysmography for rate and rhythm monitoring in atrial fibrillation
Photoplethysmography- (PPG) based smartphone applications facilitate heart rate and rhythm monitoring in patients with paroxysmal and persistent atrial fibrillation (AF). Despite an endorsement from the European Heart Rhythm Association, validation studies in this setting are lacking. Therefore, we evaluated the accuracy of PPG-derived heart rate and rhythm classification in subjects with an established diagnosis of AF in unsupervised real-world conditions. Fifty consecutive patients were enrolled, 4 weeks before undergoing AF ablation. Patients used a handheld single-lead electrocardiography (ECG) device and a fingertip PPG smartphone application to record 3907 heart rhythm measurements twice daily during 8 weeks. The ECG was performed immediately before and after each PPG recording and was given a diagnosis by the majority of three blinded cardiologists. A consistent ECG diagnosis was exhibited along with PPG data of sufficient quality in 3407 measurements. A single measurement exhibited good quality more often with ECG (93.2%) compared to PPG (89.5%; P < 0.001). However, PPG signal quality improved to 96.6% with repeated measurements. Photoplethysmography-based detection of AF demonstrated excellent sensitivity [98.3%; confidence interval (CI): 96.7–99.9%], specificity (99.9%; CI: 99.8–100.0%), positive predictive value (99.6%; CI: 99.1–100.0%), and negative predictive value (99.6%; CI: 99.0–100.0%). Photoplethysmography underestimated the heart rate in AF with 6.6 b.p.m. (95% CI: 5.8 b.p.m. to 7.4 b.p.m.). Bland–Altman analysis revealed increased underestimation in high heart rates. The root mean square error was 11.8 b.p.m. Smartphone applications using PPG can be used to monitor patients with AF in unsupervised real-world conditions. The accuracy of AF detection algorithms in this setting is excellent, but PPG-derived heart rate may tend to underestimate higher heart rates.
- Open Access
- 25 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (37) , 3672-3682
Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial
Background and Aims: In the ADVOR trial, acetazolamide improved decongestion in acute decompensated heart failure (ADHF). Whether the beneficial effects of acetazolamide are consistent across the entire range of renal function remains unclear. Methods: This is a pre-specified analysis of the ADVOR trial that randomized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The main endpoints of decongestion, diuresis, natriuresis, and clinical outcomes are assessed according to baseline renal function. Changes in renal function are evaluated between treatment arms. Results: On admission, median estimated glomerular filtration rate (eGFR) was 40 (30–52) mL/min/1.73 m². Acetazolamide consistently increased the likelihood of decongestion across the entire spectrum of eGFR (P-interaction = .977). Overall, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patients with low eGFR (both P-interaction < .007). Acetazolamide was associated with a higher incidence of worsening renal function (WRF; rise in creatinine ≥ 0.3 mg/dL) during the treatment period (40.5% vs. 18.9%; P < .001), but there was no difference in creatinine after 3 months (P = .565). This was not associated with a higher incidence of heart failure hospitalizations and mortality (P-interaction = .467). However, decongestion at discharge was associated with a lower incidence of adverse clinical outcomes irrespective of the onset of WRF (P-interaction = .805). Conclusions: Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes. ClinicalTrials.gov Identifier: NCT03505788.
- 25 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (37) , 3672-3682
Open AccessRenal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial
Background and Aims: In the ADVOR trial, acetazolamide improved decongestion in acute decompensated heart failure (ADHF). Whether the beneficial effects of acetazolamide are consistent across the entire range of renal function remains unclear. Methods: This is a pre-specified analysis of the ADVOR trial that randomized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous loop diuretics. The main endpoints of decongestion, diuresis, natriuresis, and clinical outcomes are assessed according to baseline renal function. Changes in renal function are evaluated between treatment arms. Results: On admission, median estimated glomerular filtration rate (eGFR) was 40 (30–52) mL/min/1.73 m². Acetazolamide consistently increased the likelihood of decongestion across the entire spectrum of eGFR (P-interaction = .977). Overall, natriuresis and diuresis were higher with acetazolamide, with a higher treatment effect for patients with low eGFR (both P-interaction < .007). Acetazolamide was associated with a higher incidence of worsening renal function (WRF; rise in creatinine ≥ 0.3 mg/dL) during the treatment period (40.5% vs. 18.9%; P < .001), but there was no difference in creatinine after 3 months (P = .565). This was not associated with a higher incidence of heart failure hospitalizations and mortality (P-interaction = .467). However, decongestion at discharge was associated with a lower incidence of adverse clinical outcomes irrespective of the onset of WRF (P-interaction = .805). Conclusions: Acetazolamide is associated with a higher rate of successful decongestion across the entire range of renal function with more pronounced effects regarding natriuresis and diuresis in patients with a lower eGFR. While WRF occurred more frequently with acetazolamide, this was not associated with adverse clinical outcomes. ClinicalTrials.gov Identifier: NCT03505788.
- 21 February 2023
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 20 (1) , 88-100
Spot Urinary Sodium Measurements: the Future Direction of the Treatment and Follow-up of Patients with Heart Failure
Purpose of Review Heart failure is characterized by episodes of congestion with need for hospitalization. The current metrics lack the accuracy to predict and prevent episodes of congestion and to guide diuretic titration to reach euvolemia in case of decompensation. This article aims to provide answers to the role of urinary sodium measurements in acute and chronic heart failure. Recent Findings In acute heart failure, urinary sodium concentrations at the moment of admission and after diuretic administration are correlated with short- and long-term outcome. As this is a reflection of the degree of sodium retention, it can be used as a guide in the diuretic titration. In chronic heart failure, it might be used to predict and consequently prevent episodes of decompensation. Summary Urinary sodium measurements hold great promises to be a novel diagnostic and therapeutic parameter in patients with acute and chronic heart failure. However, more research is needed.
- 21 February 2023
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 20 (1) , 88-100
Spot Urinary Sodium Measurements: the Future Direction of the Treatment and Follow-up of Patients with Heart Failure
Purpose of Review Heart failure is characterized by episodes of congestion with need for hospitalization. The current metrics lack the accuracy to predict and prevent episodes of congestion and to guide diuretic titration to reach euvolemia in case of decompensation. This article aims to provide answers to the role of urinary sodium measurements in acute and chronic heart failure. Recent Findings In acute heart failure, urinary sodium concentrations at the moment of admission and after diuretic administration are correlated with short- and long-term outcome. As this is a reflection of the degree of sodium retention, it can be used as a guide in the diuretic titration. In chronic heart failure, it might be used to predict and consequently prevent episodes of decompensation. Summary Urinary sodium measurements hold great promises to be a novel diagnostic and therapeutic parameter in patients with acute and chronic heart failure. However, more research is needed.